• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MEDTRONIC IRELAND RESOLUTE ONYX RX; CORONARY DRUG-ELUTING STENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MEDTRONIC IRELAND RESOLUTE ONYX RX; CORONARY DRUG-ELUTING STENT Back to Search Results
Device Problem Improper or Incorrect Procedure or Method (2017)
Patient Problem Obstruction/Occlusion (2422)
Event Date 02/04/2022
Event Type  Injury  
Event Description
A journal article was submitted for review titled "the resolute onyx drug eluting stent for neurointervention: a technical series".The purpose of this study was to demonstrate the technical nuances and procedural safety of the resolute onyx drug eluting stent (des) for neurointerventional procedures.The primary outcome assessed was technical success of the procedure as well as any periprocedural complications.A total of 38 patients underwent stenting with a resolute onyx des as part of this study.The resolute onyx stent was used off- label in all cases.In one case, a patient who presented with left hemiparesis and dysarthria underwent a ct angiography (cta) head and neck and ct perf usion (ctp) which revealed vertebrobasilar stenosis.Diagnostic angiography revealed diffuse intracranial vertebrobasilar atherosclerosis.The right vertebral artery was occluded at the level of the foramen magnum with near occlusion of the left vertebral artery at the vertebrobasilar junction.Given the severity of the disease, the patient underwent balloon angioplasty and stenting using 3 resolute onyx des implanted in the distal basilar artery to the distal right vertebral artery to achieve adequate recanalization.Each balloon was inflated to 8 atm to successfully deploy the stent.On post-procedure angiography, the basilar artery was patent with no residual stenosis and significantly improved flow, though the right superior cerebellar artery was occluded.Post-procedure mri demonstrated diffuse regions of diffusion restriction in the posterior circulation and an expected infarct in the right superior cerebellar artery distribution.The patient was discharged on dual antiplatelet therapy.
 
Manufacturer Narrative
Authors: timothy g white, kevin a shah, prateeka koul, thomas link, amir r dehdashti, jeffrey m katz, athos patsalides, henry h woo journal name: interventional neuroradiology year:2022 issue #: title of article: the resolute onyx drug eluting stent for neurointervention: a technical series literature reference: doi: 10.1177/15910199221084398 medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
RESOLUTE ONYX RX
Type of Device
CORONARY DRUG-ELUTING STENT
Manufacturer (Section D)
MEDTRONIC IRELAND
parkmore business park west
galway
EI 
Manufacturer (Section G)
MEDTRONIC IRELAND
parkmore business park west
galway
EI  
Manufacturer Contact
alison sweeney
parkmore business park west
galway 
EI  
091708096
MDR Report Key15876725
MDR Text Key304425734
Report Number9612164-2022-04459
Device Sequence Number1
Product Code NIQ
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P160043
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Literature
Reporter Occupation Physician
Type of Report Initial
Report Date 11/29/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Health Professional
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 11/02/2022
Initial Date FDA Received11/29/2022
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Other;
Patient Age64 YR
Patient SexMale
-
-